Although this system is mainly controlled by alterations in the receptor activator of NF‐κB ligand (RANKL), RANKL‐based treatment does not prolong the overall survival of patients with PCa bone metastasis. The gene discussed is TNFSF11; the disease is posterior cortical atrophy.